Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 7/20 | 0.68 |
| ▸ | PARP15 | Q460N3 | 2/20 | 0.55 |
| ▸ | PARP4 | Q9UKK3 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.55 |
| ▸ | PARP16 | Q8N5Y8 | 1/20 | 0.55 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.55 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.54 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.53 |
| ▸ | TMPRSS2 | O15393 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | PARP1 | P09874 | 1/20 | 0.52 |
| ▸ | PRMT1 | Q99873 | 3/20 | 0.52 |
| ▸ | F2 | P00734 | 2/20 | 0.52 |
| ▸ | ST14 | Q9Y5Y6 | 2/20 | 0.52 |
| ▸ | PLAU | P00749 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3082936 | 0.94 | PARP10 (0.66) | PARP10PARP15PARP4ALDH1A1KMT2A | |
| SCHEMBL3085074 | 0.92 | PARP10 (0.68) | PARP10PARP15PARP4ALDH1A1KMT2A | |
| SCHEMBL1787654 | 0.87 | PARP10 (0.62) | PARP10PARP15PARP4ALDH1A1KMT2A | |
| SCHEMBL1086686 | 0.85 | PARP10 (0.72) | PARP10L3MBTL1GAA | |
| Water SCHEMBL5055924 | 0.85 | PARP10 (0.68) | PARP10PARP15PARP4ALDH1A1KMT2A | |
| SCHEMBL27987025 | 0.85 | PARP10 (0.68) | PARP10PARP15PARP4ALDH1A1KMT2A | |
| SCHEMBL4687732 | 0.85 | PARP10 (0.68) | PARP10PARP15PARP4ALDH1A1KMT2A | |
| SCHEMBL27972513 | 0.84 | PARP10 (0.66) | PARP10PARP15PARP4ALDH1A1KMT2A | |
| SCHEMBL12516203 | 0.84 | GAA (0.59) | ALDH1A1KMT2AL3MBTL1GAA | |
| SCHEMBL7957567 | 0.83 | PARP10 (0.66) | PARP10PARP15PARP4ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2532651-B1 | Synthesis process, and crystalline form of 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide hydrochloride and its free base as well as the pharmaceutical compositions containing them | SERVIER LAB (FR) | 2015-08-05 | — | — | EP | claimed |
| US-8952179-B2 | Synthesis process, and crystalline form of 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1H)-yl]propoxy} benzamide hydrochloride and pharmaceutical compositions containing it | LES LABORATORIES SERVIER (FR) | 2015-02-10 | — | — | US | claimed |
| US-20140100374-A1 | SYNTHESIS PROCESS, AND CRYSTALLINE FORM OF 4- BENZAMIDE HYDROCHLORIDE AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT | LES LABORATOIRES SERVIER (FR) | 2014-04-10 | — | — | US | claimed |
| WO-2012168657-A1 | PROCESS FOR SYNTHESIS AND CRYSTALLINE FORM OF 4-{3-[CIS-HEXAHYDROCYCLOPENTA[C]PYRROL-2(1H)-YL]PROPOXY}BENZAMIDE HYDROCHLORIDE, IN ADDITION TO THE ASSOCIATED FREE BASE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | LES LABORATOIRES SERVIER (FR) | 2012-12-13 | — | — | WO | claimed |
| US-20120316214-A1 | SYNTHESIS PROCESS, AND CRYSTALLINE FORM OF 4-BENZAMIDE HYDROCHLORIDE AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT | LES LABORATOIRES SERVIER (FR) | 2012-12-13 | — | — | US | claimed |
| EP-2532651-A1 | Synthesis process, and crystalline form of 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide hydrochloride and its free base as well as the pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2012-12-12 | — | — | EP | claimed |
| EP-2532651-B1 | Synthesis process, and crystalline form of 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide hydrochloride and its free base as well as the pharmaceutical compositions containing them | SERVIER LAB (FR) | 2015-08-05 | — | — | EP | disclosed |
| US-8952179-B2 | Synthesis process, and crystalline form of 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1H)-yl]propoxy} benzamide hydrochloride and pharmaceutical compositions containing it | LES LABORATORIES SERVIER (FR) | 2015-02-10 | — | — | US | disclosed |
| US-20140155453-A1 | SYNTHESIS PROCESS, AND CRYSTALLINE FORM OF 4-{3[CIS-HEXAHYDROCYCLOPENT A[CjPYRROL-2( 1 H)-YLjPROPOXYj BENZAMI DE HYDROCHLORI DE AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT | LES LABORATOIRES SERVIER (FR) | 2014-06-05 | — | — | US | disclosed |
| US-20140100374-A1 | SYNTHESIS PROCESS, AND CRYSTALLINE FORM OF 4- BENZAMIDE HYDROCHLORIDE AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT | LES LABORATOIRES SERVIER (FR) | 2014-04-10 | — | — | US | disclosed |
| US-8664408-B2 | Synthesis process, and crystalline form of 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1H)-yl]proxy}benzamide hydrochloride and pharmaceutical compositions containing it | LES LABORATOIRES SERVIER (FR) | 2014-03-04 | — | — | US | disclosed |
| CN-102127004-B | Azabicyclo[3.2.0]hept-3-yl, method for preparing same and pharmaceutical compositions containing them | SERVIER LAB | 2013-10-23 | — | — | CN | disclosed |
| EP-2332910-B1 | New derivatives of azabicyclo[3.2.0]hept-3-yl, method for preparing same and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2013-01-30 | — | — | EP | disclosed |
| EP-1866293-A1 | COMPOUNDS COMPRISING AN OXAZOLE OR THIAZOLE MOIETY, PROCESSES FOR MAKING THEM, AND THEIR USES | UCB Pharma, S.A. (BE) | 2007-12-19 | — | — | EP | disclosed |
| WO-2006103045-A1 | COMPOUNDS COMPRISING AN OXAZOLE OR THIAZOLE MOIETY, PROCESSES FOR MAKING THEM, AND THEIR USES | UCB PHARMA S.A. (BE) | 2006-10-05 | — | — | WO | disclosed |
| US-4950674-A | Arylalkylheterocyclic amines,N-substituted by aryloxyalkyl group in a method for allergy treatment | A. H. ROBINS COMPANY, INCORPORATED (US) | 1990-08-21 | — | — | US | disclosed |
| US-4895840-A | ANTIARRHYTHMIA AGENTS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1990-01-23 | — | — | US | disclosed |
| US-4810713-A | Arylalkyl-heterocyclic amines, n-substituted by aryloxyalkyl groups used in a method for allergy treatment | A. H. ROBINS COMPANY, INCORPORATED (US) | 1989-03-07 | — | — | US | disclosed |
| EP-0295010-A1 | Derivatives of alkylaminoalkyl ureas and cyanoguanidines | A.H. ROBINS COMPANY, INCORPORATED (US) | 1988-12-14 | — | — | EP | disclosed |
| EP-0235463-A2 | N-substituted-arylalkyl and arylalkylene piperidines as cardiovascular antihistaminic and antisecretory agents | A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) (US) | 1987-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155453-A1 | SYNTHESIS PROCESS, AND CRYSTALLINE FORM OF 4-{3[CIS-HEXAHYDROCYCLOPENT A[CjPYRROL-2( 1 H)-YLjPROPOXYj BENZAMI DE HYDROCHLORI DE AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT | HRH2, HRH1, HRH4 | PARP10 4568/4885PARP15 3819/4885PARP4 4144/4885 |
| US-20120316214-A1 | SYNTHESIS PROCESS, AND CRYSTALLINE FORM OF 4-BENZAMIDE HYDROCHLORIDE AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT | HRH4, HRH2, HRH1 | PARP10 3022/4885PARP15 1834/4885PARP4 1385/4885 |
| US-20140100374-A1 | SYNTHESIS PROCESS, AND CRYSTALLINE FORM OF 4- BENZAMIDE HYDROCHLORIDE AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT | CYP4B1, CYP3A4, CYP4F8 | PARP10 2733/4885PARP15 1116/4885PARP4 665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.